SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Three-Year trial tests Long-Term safety of new lupus injection
Disease control ENROLLING_BY_INVITATIONThis study aims to learn about the long-term safety and effectiveness of a drug called litifilimab for adults with active systemic lupus erythematosus (SLE). It is an extension study for about 864 people who completed a previous 1-year trial, and will follow them for up to 3.5 ye…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Apr 01, 2026 21:26 UTC
-
Scientists test 'Switchable' CAR-T cells to tame the Body's own immune attack
Disease control TerminatedThis early-stage study aimed to test a new two-part treatment for serious autoimmune diseases like lupus and scleroderma. The treatment involved collecting a patient's own immune cells (T cells), engineering them in a lab, and then infusing them back alongside a control drug. The…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Scientists test 'Living Drug' to reboot immune system in devastating autoimmune conditions
Disease control ENROLLING_BY_INVITATIONThis is an early-stage study testing a new type of cell therapy called Prula-cel for adults with severe autoimmune diseases that haven't responded well to standard treatments. The therapy involves giving patients specially engineered immune cells designed to target and remove har…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
First test of new lupus shot begins in humans
Disease control OngoingThis is the first study in people for a new potential lupus treatment called SG301. It aims to first check the safety of a single dose in healthy volunteers, and then test multiple doses in people with mild-to-moderate lupus. The main goal is to see how safe the drug is and how t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Experimental cell therapy tested for Hard-to-Treat lupus
Disease control OngoingThis study is testing whether a new type of cell therapy called Descartes-08 is safe and feasible for people with systemic lupus erythematosus (SLE). It involves 6 adult patients whose lupus symptoms remain active despite trying multiple standard medications. The main goal is to …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New lupus treatment begins human testing
Disease control OngoingThis is the first human study of an experimental drug called KK4277 for lupus. Researchers are testing the safety and side effects of single and multiple doses in healthy volunteers and people with different types of lupus. The study will also measure how much of the drug gets in…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Mar 02, 2026 15:27 UTC